Abstract
Given that atazanavir (ATV) increases bilirubin in an exposure-dependent manner, we tested whether bilirubin levels could be used as a surrogate of virological response to ATV-based regimens in 182 patients. Bilirubin increases of ≥0.7 mg/dl were independently associated with early virological response with an odds ratio of 5.2 (95% confidence interval 2.2-11.9). Total bilirubin, a nonexpensive, simple, and widely available parameter, might be used as a surrogate of virological response to ATV-based regimens, especially in areas with limited resources where HIV-RNA testing is not available.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Alleles
-
Atazanavir Sulfate
-
Bilirubin / blood
-
Biomarkers / blood
-
CD4 Lymphocyte Count
-
Coinfection / blood
-
Coinfection / drug therapy
-
Coinfection / virology
-
Female
-
Follow-Up Studies
-
Glucuronosyltransferase / genetics
-
HIV / pathogenicity
-
HIV Infections / blood
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV Protease Inhibitors / adverse effects
-
HIV Protease Inhibitors / therapeutic use*
-
Hepatitis C / blood
-
Hepatitis C / virology
-
Humans
-
Male
-
Middle Aged
-
Odds Ratio
-
Oligopeptides / adverse effects
-
Oligopeptides / therapeutic use*
-
Pyridines / adverse effects
-
Pyridines / therapeutic use*
-
RNA, Viral / blood*
-
ROC Curve
-
Regression Analysis
-
Retrospective Studies
-
Viral Load
Substances
-
Biomarkers
-
HIV Protease Inhibitors
-
Oligopeptides
-
Pyridines
-
RNA, Viral
-
Atazanavir Sulfate
-
UGT1A1 enzyme
-
Glucuronosyltransferase
-
Bilirubin